Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Vertex Pharmaceuticals Stock Jumps
Vertex Pharmaceuticals CEO on non-opioid painkiller: It's safe, effective and non-addictive
CNBC’s Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the FDA's approval of the company's non-opioid painkiller pill Journavx, a new alternative for pain relief that comes without the risk of addiction,
Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.
England, Vertex Pharmaceuticals and Sickle Cell Disease
Vertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in England
Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to treat sickle cell disease. Read more here.
Vertex In CASGEVY Reimbursement Deal With NHS England For Sickle Cell Disease Patients
Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY ® (exagamglogene autotemcel).
1h
Vertex Pharmaceuticals price target raised to $433 from $430 at Scotiabank
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares.
5h
on MSN
These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Exxon, and More
Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Black boxes recovered
Los Angeles wildfire updates
Cause of death revealed
Apologizes for old tweets
Activists call for boycott
Top leaders asked to resign
Inmate's transfer blocked
Asteroid may hit Earth
Sexual misconduct accusation
Michigan priest loses license
Recuses self from Act 10 suit
To raise hourly pay
Hamas confirms death
Olympic gold medalist dies
Deputy shooting sentence
'As Tears Go By' singer dies
Nashville bids for franchise
Ground stop amid IT outage
Ex-worker admits to theft
FDA approves painkiller
Blames DEI for crash
Confirmed interior secretary
S3 release date revealed
2 more victims in indictment
Weekly jobless claims fall
Searching for joyriders
Ebola outbreak in Uganda
DOJ sues to block deal
Shiffrin finishes 10th
Related topics
Journavx
Apple
Trade
Non-Opioid Painkiller
Food and Drug Administration
Feedback